The article discusses the August 2016 refusal of the U.S. Drug Enforcement Agency (DEA) to reclassify marijuana under the federal Controlled Substances Act. Topics include the therapeutic benefits offered by medical marijuana, the need for scientists to lessen the outsized influence of DEA on medical decisions, and their imperative to rebuild their credibility as scientists on the issue of marijuana.
© 2001-2025 Fundación Dialnet · Todos los derechos reservados